论文信息 - Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma, - 字舞流文

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Jeffrey A Jones | J. Byrd | R. Baiocchi | K. Blum | P. Porcu | J. Flynn | M. Phelps | B. Christian | M. Poi | D. Benson | L. Alinari | D. Goldenberg | W. Wegener | M. Lustberg | C. Quinion | D. Chung